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Abstract
Background: This study was designed to determine if a natural mineral supplement, sierrasil, alone and in combination
with a cat's claw extract (Uncaria guianensis), vincaria, has therapeutic potential in mild to moderate osteoarthritis of the
knee.
Methods: Patients (n = 107) with mild to moderate osteoarthritis of the knee were randomly assigned to one of 4
groups; high dose sierrasil (3 g/day), low dose sierrasil (2 g/day), low dose sierrasil (2 g/day) + cat's claw extract (100 mg/
day) or placebo, administered for 8 weeks. Treatment was double blinded. Primary efficacy variables were WOMAC
scores (A, B, C and total). Visual analog score (VAS) for pain, consumption of rescue medication (paracetamol), and
tolerability were secondary variables. Safety measures included vital signs and laboratory-based assays.
Results: Ninety-one of the 107 patients successfully completed the protocol. All four groups showed improvement in
WOMAC and VAS scores after 8 weeks (p < 0.001), in all 3 groups receiving sierrasil the magnitude of benefits were
greater vs. placebo (WOMAC Total 38–43% vs. 27%) but this was not statistically significant. In reference to baseline
values sierrasil treated groups had a considerably faster onset of benefits. Placebo-treated individuals failed to show
significant benefits at 4 weeks (11% reduction in total WOMAC). In contrast, after 1 or 2 weeks of therapy all the sierrasil
groups displayed significant reductions in WOMAC scores (p < 0.05) and at week 4 displayed a 38–43% improvement.
VAS was significantly improved at 4 weeks in all groups (p < 0.001) but was significantly greater in all sierrasil groups
compared to placebo (p < 0.05). Rescue medication use was 28-23% lower in the herbomineral combination and high
dose sierrasil groups although not statistically different from placebo (P = 0.101 and P = 0.193, respectively). Tolerability
was good for all groups, no serious adverse events were noted and safety parameters remained unchanged.
Conclusion: The natural mineral supplement, sierrasil alone and in combination with a cat's claw extract, improved joint
health and function within 1–2 weeks of treatment but significant benefits over placebo were not sustained, possibly due
to rescue medication masking. Sierrasil may offer an alternative therapy in subjects with joint pain and dysfunction.
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Background
Osteoarthritis is a painful and debilitating joint condition
that affects hundreds of millions worldwide [1]. Despite
the prevalence of the disease, current therapeutic options
are not optimal. Pharmaceutical approaches to disease
management include the popular non-steroidal anti-
inflammatory class (NSAIDs) which block cyclo-oxygen-
ase (COX). NSAIDS provide symptomatic relief [2] but do
not abrogate the underlying disease process. Moreover,
therapy has recently been dominated by the COX-2 spe-
cific class, which was designed to reduce unwarranted
renal and gastrointestinal side-effects associated with
non-specific COX inhibitors [3]. However, recent studies
have revealed heightened cardiovascular risks [4,5], which
may limit the application of the COX-2 specific class of
NSAIDs.
Use of complimentary medicine as an alternative thera-
peutic approach is common in conditions associated with
pain and discomfort and especially when local traditions
support such approaches. Examples of complimentary
medicines that have been proposed to offer benefits for
osteoarthritis include acupuncture [6], nutraceuticals [7-
9] and botanicals [10,11]. Additionally, various forms of
physical therapy offer established non-pharmacologic
benefits [12].
Of the nutraceutical approaches one of the best known
and widely used is glucosamine (alone or in combination
with chondroitin). Glucosamine and chondroitin are
structural elements of cartilage and matrix. The therapeu-
tic approach centers on the assumption that ingestion of
large amounts of these matrix elements will assist in the
replacement of the comparable material that is lost as a
result of the catabolic process associated with inflamma-
tion. Recently, it has been suggested that the absorption of
oral glucosamine is not sufficient for the chondroitin pro-
duction and cartilage deposition [13]. There is limited evi-
dence for a direct anti-inflammatory action of
glucosamine [14]. Nevertheless by design it is not an
approach that influences the disease process directly, but
rather is thought to maintain cartilage architecture in the
face of ongoing catabolic pathways. Hence, not surpris-
ingly, the onset of action in those individuals for whom it
does provide relief is commonly on the order of months
after treatment initiation [15-17]. Studies as to the efficacy
of glucosamine and chondroitin have produced variable
results [18-21] suggesting that the benefits of this
approach may have limitations.
Botanicals, especially those with redox-based actions are
promising in the treatment of chronic inflammation
because of their inherent disease modifying characteris-
tics. Green tea catechins, especially epigallocatechin gal-
late (EGCG), have been shown to limit human cartilage
degradation in vitro [22,23] and maintain joint architec-
ture in an animal model [24]. This anti-inflammatory
action is thought to be the result of inhibition of transcrip-
tional events, particularly prevention of NF-κB activation
by cytokines and oxidants. NF-κB is a critical transcription
factor in chronic inflammation and is a desirable target for
new therapeutics, including pharmaceutical develop-
ment, as it regulates numerous genes that contribute to
the inflammatory process [25-27]. Of particular note for
joints NF-κB regulates the production of matrix metallo-
proteases (MMPs) by chondrocytes [28]. During inflam-
mation or injury chondrocytes release MMPs, which in
turn degrade the cartilage matrix, releasing gly-
cosaminoglycans and eventually, glucosamine. Haqqi
and colleagues have elegantly demonstrated how EGCG
can prevent MMP formation and cartilage degradation in
explants of human cartilage stimulated by the pro-inflam-
matory cytokine, IL-1β [22] and reviewed the use of
botanicals, in general, as arthritis therapeutics [11].
Sierrasil® is a natural mineral product derived from the
Sierra Mountains in the USA that has a cultural history of
use to treat joint pain. We have recently demonstrated in
the Haqqi model of human cartilage explants, that
extracts of sierrasil reduced cartilage degradation in
response to IL-1β, as well as nitric oxide production sec-
ondary to the induction of inducible nitric oxide synthase
[29,30]. Increased chondrocyte production of nitric oxide
is associated with catabolic activities and inhibitors of
inducible nitric oxide synthase display anti-inflammatory
properties [23,30-35]. While an action of sierrasil was not
directly assessed on transcriptional events nevertheless,
that is a likely target based on its ability to suppress IL-1β
mediated events in human cartilage.
In the human cartilage explant study with sierrasil, co-
administration of an extract of the botanical cat's claw
(Uncaria guianensis, Vincaria®) complimented these
actions. Indeed, this Uncaria guianensis extract is a remark-
ably potent inhibitor of NF-κB activity and tumor necrosis
factor (TNFα) production [36-38], with clear cytoprotec-
tive actions [39] and has already successfully completed a
placebo controlled trial for osteoarthritis of the knee [10].
Cat's claw is a vine indigenous to the Amazon Rainforest,
that has a long history of use for joint pain and chronic
inflammation [40].
Given that sierrasil was able to limit human cartilage deg-
radation induced by IL-1β in vitro [29], it was determined
that further study in human osteoarthritis was warranted.
Further, it was postulated that based on the acute in vitro
observations on cartilage protection and suppression of
inflammatory events sierrasil may result in a clinical
response that was expedient. Given the complimentary
actions in vitro with cat's claw, a combination therapy wasJournal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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also evaluated. The goal was to determine if these
approaches offered benefits in a safe manner, over the
course of two months of treatment with a focus on rapid
induction of benefits.
Methods
Research Design
This randomized, double-blind, placebo-controlled
multi-center trial was approved by the Institutional Ethics
Committee of K.J. Somaiya Medical College & Hospital,
Mumbai, India and was in compliance with the Helsinki
Declaration.
Participants
Subjects were recruited from three centers – two private
arthritis clinics and the K.J. Somaiya Medical College &
Hospital, in Mumbai, India. Inclusion criteria were ambu-
latory, adult patients of either sex and greater than 20
years of age. Mild to moderate osteoarthritis was deter-
mined by radiological examination and ARA functional
class II or III, and Kellgren Lawrence classification for knee
osteoarthritis grade II or Grade III, and a baseline func-
tional assessment of overall pain of at least 50 mm on a
100 mm Visual Analog Scale.
Exclusion criteria were osteoarthritis of grade I or IV (Kel-
lgren Lawrence or ARA functional class), existence of other
forms of arthritis, arthroscopy of either knee within the
past year, administration of intra-articular steroids within
the past 3 months or hyaluronic acid in the last 9 months,
pregnancy or lactating women or women not taking ade-
quate contraceptive measures, presence of any concomi-
tant unstable disease or abnormality of any clinically
relevant laboratory test, evidence of severe renal or hema-
tologic disease or severe cardiac insufficiency, moderate to
severe neuropathy, and unwillingness to come to regular
follow-up visits for the length of the study.
A Fixed Allocation Randomization procedure was used to
assign interventions to the participants with a pre-speci-
fied probability. Randomization was done in blocks of
four, related to the number of treatment groups, and the
total possibilities were 24. Treatment codes were held in a
sealed manner by investigators in case of a serious adverse
event. The allocation sequence was generated by the con-
sulting statistician and subjects were assigned treatment
according to this algorithm until subject 96 (total possi-
bilities) and then the same cycle was repeated. Allocation
of treatment according to this method was assigned by
authors (SK, KM) along with monitoring of trial supplies,
blindness, and adverse event monitoring. Research coor-
dinators however, were not involved in any trial related
activities to avoid bias.
For ease of presentation the 4 subject groups are given the
following descriptors:
Group A – High dose sierrasil
Group B – Low dose sierrasil
Group C – Low dose sierrasil plus cat's claw extract
Group D – Placebo
A total of 107 subjects were recruited based on a planned
recruitment of 25 subjects per group (total of 100). This
recruiting estimate was based on results obtained in a trial
Table 1: Mineral composition of Sierrasil and the expected 
intake at the low (2 g/day) and high (3 g/day) doses. Mineral 
bioavailability in the various forms has not been established but 
data on acid liberalization suggest that for some minerals the 
dose available for absorption may be as low as < 0.1%.
Metal assays 
(ICP-MS)
Total Intake at
 2 g/day dose
Total Intake at
 3 g/day dose
Aluminum 188 mg/day 282 mg/day
Antimony < 0.006 mg/day < 0.009 mg/day
Arsenic 0.026 mg/day 0.035 mg/day
Barium 2.0 mg/day 2.9 mg/day
Beryllium < 0.002 mg/day < 0.003 mg/day
Bismuth < 0.06 mg/day < 0.09 mg/day
Cadmium 0.0036 mg/day 0.0054 mg/day
Calcium 26 mg/day 40 mg/day
Carbon 0.60 mg/day 0.90 mg/day
Chromium 0.040 mg/day 0.060 mg/day
Chromium (VI) < 0.00048 mg/day < 0.00072 mg/day
Cobalt 0.017 mg/day 0.026 mg/day
Copper 0.074 mg/day 0.11 mg/day
Iron 119 mg/day 178 mg/day
Lead 0.013 mg/day 0.020 mg/day
Lithium 0.02 mg/day 0.03 mg/day
Magnesium 11 mg/day 17 mg/day
Manganese 0.29 mg/day 0.44 mg/day
Mercury 0.0012 mg/day 0.0017 mg/day
Molybdenum 0.002 mg/day 0.003 mg/day
Nickel 0.027 mg/day 0.040 mg/day
Phosphorous 3.8 mg/day 5.7 mg/day
Potassium 20 mg/day 30 mg/day
Selenium 0.0030 mg/day 0.0045 mg/day
Silica 899 mg/day 1349 mg/day
Silver 0.015 mg/day 0.022 mg/day
Sodium < 12 mg/day < 18 mg/day
Strontium 2.1 mg/day 3.2 mg/day
Sulphur 30 mg/day 45 mg/day
Thorium < 0.010 mg/day < 0.015 mg/day
Tin < 0.02 mg/day < 0.03 mg/day
Titanium 10 mg/day 15 mg/day
Uranium < 0.12 mg/day < 0.18 mg/day
Vanadium 0.34 mg/day 0.51 mg/day
Zinc 0.082 mg/day 0.12 mg/day
Zirconium 0.23 mg/day 0.35 mg/dayJournal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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which demonstrated efficacy with the cat's claw extract
alone [10].
The sequence of the study involved an assessment of vital
signs, radiological assessment of the affected knee and
laboratory tests one week before baseline. Laboratory tests
included: complete blood count, erythrocyte sedimenta-
tion rate, SGPT, serum creatinine, urine pregnancy test. At
baseline the following were recorded – vital signs,
WOMAC score (A, B, C and total) and VAS. This was
repeated at weeks 1, 2, 4, 6, and 8 after treatment initia-
tion along with monitoring of compliance and adverse
event monitoring. At the conclusion of the study at week
8, laboratory tests were repeated.
Patients were considered drop-outs from the study if they
went more than 4 days without medication or failed to
report within the fifth day of a scheduled visit. Protocol
deviation was characterized by not attending a scheduled
visit by more than one day, skipping medication for an
entire day, consuming other medications without consult-
ing the investigator and not bringing the rescue medica-
tion or study medication bottles at the time of a scheduled
visit.
Patients were not allowed to consume any NSAIDs, anal-
gesics, cartilage supplements, calcium supplements, ster-
oids, or other agents that may affect the outcomes of the
study other than the rescue medication. Any medication
taken by subjects for two months prior to the inclusion of
the study, and whose intake was stabilized, was permitted
and monitoring that dosing of these medications was not
changed for the duration of the investigation.
Treatments
The duration of treatment was 8 weeks, administered as 2
capsules twice a day taken orally with meals. The rescue
medication was paracetamol (acetaminophen) as a single
tablet of 500 mg, at a dosage that was not to exceed 4 tab-
lets a day.
Sierrasil® is a 100% natural composite, yet novel compos-
ite mineral (SM317) containing silicate minerals of cal-
cium, magnesium, potassium, sodium and aluminum,
among others. Sierrasil contains primarily 45.0% SiO2
(silica), 9.5% aluminum (as aluminum silicate), 5.9%
iron (in several mineral forms), 1.3% calcium (in various
forms), and other trace elements (Table 1). Sierrasil alone
was administered in two treatment groups. The high dose
group received a total of 3 g/day, and the low dose group
2 g/day. In addition, there was a separate treatment group
where low dose sierrasil (2 g/day) was combined with a
cat's claw extract, vincaria® (Uncaria guianensis) at a dose of
100 mg/day. The relative components of major mineral
sources in sierrasil are noted in Table 1, along with the
expected daily intake at the doses of 2 and 3 grams.
Cat's claw is an Amazonian vine whose bark has a long
history of ethnomedical use for treating inflammation
[38,40]. Commonly two species are used Uncaria tomen-
tosa and Uncaria guianensis, and the Vincaria® extract uses
the Uncaria guianensis species, which was chosen as it is
has been shown to be more potent as an anti-inflamma-
tory agent [38], and is the only source of cat's claw with
documented benefits in osteoarthritis [10]. The vincaria
extract, which is a water based extraction, is devoid of
oxindole alkaloids [38], present in Uncaria tomentosa that
are thought to be immune enhancing [41,42], and there-
fore counter-productive for this application.
Sierrasil (SM317) was obtained from the manufacturer,
Sierra Mountain Minerals, Inc. Bozeman, MT, USA http://
www.sierrasil.com and Vincaria cat's claw (RN180) was
Table 2: Modified WOMAC Questionnaire. Subjects responded 
with the following numerical assessment: 0 = none; 1 = slight; 2 = 
moderate; 3 = severe; 4 = extreme
WOMAC A: Pain on
- Walking
- Stair climbing
- Nocturnal
- Rest
- Weight bearing
WOMAC B: Stiffness
- In morning
- Stiffness occurring during the day
WOMAC C: Level of difficulty performing the following 
functions:
- Descending stairs
- Ascending stairs
- Rising from sitting
- Standing
- Bending to the floor
- Walking on flat
- Getting in/out of a car
- Going shopping
- Putting on socks-Rising from bed
- Taking off socks
- Lying in bed
- Getting in/out of bath
- Sitting
- Getting on/off toilet
- Heavy domestic duties
- Light domestic duties
- While working
- Sitting cross legged
- While cycling
- While driving vehicle
- While praying.Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
Page 5 of 14
(page number not for citation purposes)
obtained from Rainforest Nutritionals, Inc., Raleigh, NC,
USA http://www.rainforest-inc.com. Sierrasil and vincaria
are produced under GMP conditions. Vincaria is standard-
ized to a maximum level of oxindole alkaloids of 0.3 mg/
g and an IC50 for TNF αinhibition of at least 1 ug/ml. Lac-
tose was used as the placebo and as a filler for treatment
group capsules to ensure that all treatments were uniform
in size and color. Uniformity was maintained for all four
treatment groups in terms of bottle filling, labeling, and
packaging. Treatments were packaged in gelatin capsules
and packed in wide mouthed white opaque plastic bottles
with screw caps in a clean room. Investigators were pro-
vided with blinding chits having patient codes along with
their treatment group (alphabetical code). In the case of a
serious adverse event investigators were instructed to
inform the monitors and then only unblind the treatment
group of the subject in order to address needful treatment.
Primary Efficacy Variable
The Western Ontario and McMaster Universities
(WOMAC) Osteoarthritis Index is a disease-specific self-
administered, health status measure that is widely
accepted as reflective of osteoarthritis disease activity. The
original index consists of 24 questions (5 pain, 2 stiffness
and 17 physical functions). Individual question responses
are assigned a score of between 0 (none) to 4 (extreme)
and summed to form a score ranging from 0 (best) to 96
(worst). There are three sections to the WOMAC Score.
Section A deals with the amount of pain (5 questions).
Section B addresses the amount of joint stiffness (2 ques-
tions). Section C addresses aspects of physical function (17
questions).
In section C of the WOMAC Score 5 questions were add-
edfor a total of 22 questions. This score was then normal-
ized to produce a total WOMAC score in a range of 0–100.
Table 3: Baseline characteristics of treatment groups
Placebo Group A Group B Group C
N completed (started) 23 (29) 20 (25) 22 (24) 26 (29)
Age (years) 51.3 ± 1.0 50.5 ± 1.7 52.3 ± 1.8 52.1 ± 1.6
Gender (F: M %) 72:28 76:24 75:25 52:48
ARA Functional Class II/III, % 69 : 31 76 : 24 67 : 33 69 : 31
Kellgren Lawrence Criteria Grade 2/3, % 76 : 24 83 : 17 83 : 17 82 : 18
WOMAC A 8.7 ± 1.0 9.1 ± 1.2 8.0 ± 1.1 8.7 ± 1.0
WOMAC B 3.4 ± 0.5 3.5 ± 0.5 3.3 ± 0.4 3.3 ± 0.4
WOMAC C 36.4 ± 3.9 38.4 ± 4.0 34.7 ± 4.2 32.8 ± 4.3
WOMAC Total 48.6 ± 5.2 51.1 ± 6.4 46.4 ± 5.6 44.8 ± 5.5
VAS 72.9 ± 2.0 72.9 ± 3.0 70.1 ± 2.5 70.7 ± 2.4
Data expressed as a % of total or mean ± sem. Group A = High dose sierrasil, Group B = Low dose sierrasil, Group C = Low dose sierrasil + cat's 
claw extract. None of the entry assessments were significantly different amongst the four randomized groups.
Table 4: Sequential WOMAC A Scores – Pain
Group Baseline Week 1 Week 2 Week 4 Week 6 Week 8
Placebo 8.7 ± 1.0 8.9 ± 1.1 8.5 ± 1.2 8.4 ± 1.2 6.8 ± 1.1 * 6.3 ± 1.2 *
A 9.1 ± 1.2 8.1 ± 1.2 * 7.5 ± 1.2 ** 6.5 ± 1.2 ** 6.4 ± 1.2 ** 6.3 ± 1.1 **
B 8.0 ± 1.1 7.5 ± 1.1 6.9 ± 1.1 ** 5.7 ± 1.0 ** 5.6 ± 1.1 ** 5.0 ± 0.9 **
C 8.7 ± 1.0 8.0 ± 1.0b 6.9 ± 0.9 *** 5.6 ± 0.8 *** 5.0 ± 0.8 *** 4.3 ± 0.7 ***
Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + 
cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the 
Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, *** p < 
0.001.Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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Details of all questions included, per section, are found in
Table 2. The addition of questions to the Section C com-
ponent of WOMAC, which primarily addresses physical
function, may be skewed the WOMAC total score away
from pain and stiffness. Nevertheless, the pain and stiff-
ness components were assessed individually, as well as
collectively, to ensure that specific benefits could be ascer-
tained as well as a modified global assessment.
Secondary Efficacy Variables
VAS – Visual Analog Score uses a 100 mm linear measure
of pain status, with 0 representing no pain and 100 being
unbearable pain. Patients marked on the linear scale the
relevant amount of pain they were experiencing and the
value was noted by the investigator.
Recovery, as assessed by investigator and physician, was
characterized by 5 categories: Excellent – complete relief
of symptoms; Good – partial relief of symptoms; Fair –
minimal relief of symptoms; poor – no relief of symp-
toms; very poor – worsening of symptoms.
Tolerability was assessed by 3 categories. Good – no side
effects; Fair – mild to moderate side effects; poor – severe
side effects and withdrawal of therapy. Measurements of
recovery and tolerability were performed at the end of the
protocol (week 8).
Use of rescue medication, paracetamol (acetominophen)
was addressed as a measure of both pain management
and efficacy. The amount of rescue medication was only
assessed in terms of total use at the conclusion of the
study period. Rescue medication use was not assessed
sequentially along with other variables.
Data Quality Assurance
All investigators were informed of ICH-GCP guidelines,
the quality of data and study execution was monitored by
individuals independent of subject contact and treatment
assessment.
Statistical Analysis
Data was analyzed by an independent statistician using
the following tests – ANOVA, paired and unpaired t tests,
Bonferroni, Chi Square, Friedman and Wilcoxan tests as
appropriate. The following software was used: SPSS 11.5,
PEPI, EPI INFO 2000 and MS Excel. Statistical significance
was taken at the 95% level (p < 0.05). Results are
expressed as the mean ± SEM.
Table 5: Sequential WOMAC B Scores – Joint Stiffness
Group Baseline Week 1 Week 2 Week 4 Week 6 Week 8
Placebo 3.4 ± 0.5 3.6 ± 0.5 3.1 ± 0.5 3.0 ± 0.5 2.6 ± 0.5 * 2.4 ± 0.5 *
A 3.5 ± 0.5 3.0 ± 0.5 * 2.9 ± 0.6 * 2.4 ± 0.5 ** 2.4 ± 0.5 ** 2.3 ± 0.5 **
B 3.3 ± 0.4 2.9 ± 0.5 * 2.6 ± 0.5 ** 2.1 ± 0.4 ** 2.2 ± 0.5 ** 1.9 ± 0.3 **
C 3.3 ± 0.4 3.2 ± 0.4 3.0 ± 0.4 2.1 ± 0.3 *** 2.0 ± 0.3 *** 1.6 ± 0.4 ***
Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + 
cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the 
Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, *** p < 
0.001.
Table 6: Sequential WOMAC C Scores – Physical Function
Group Baseline Week 1 Week 2 Week 4 Week 6 Week 8
Placebo 36.4 ± 3.9 37.0 ± 4.3 35.0 ± 4.4 32.0 ± 4.3 29.5 ± 4.5 26.6 ± 4.6 **
A 38.4 ± 4.9 32.4 ± 5.3 31.0 ± 5.1 ** 26.1 ± 4.6 *** 26.3 ± 4.6 *** 23.1 ± 4.6 ***
B 34.7 ± 4.2 31.3 ± 4.4 * 28.7 ± 4.4 ** 24.5 ± 3.8 *** 22.8 ± 3.9 *** 21.3 ± 2.9 ***
C 32.8 ± 4.3 31.1 ± 4.0 29.1 ± 4.0 * 24.3 ± 3.4 *** 21.7 ± 3.5 *** 19.7 ± 3.4 ***
Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + 
cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the 
Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, *** p < 
0.001.Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
Page 7 of 14
(page number not for citation purposes)
Results
Patient Randomization
Patient randomization was effective. Subject age was com-
parable in all groups (Table 3). Gender was predomi-
nantly female 73/107 (68.2%) vs. males 34/107 (31.8%).
At entry 70% of subjects had ARAF-Class II and 30%
ARAF-Class III. A similar distribution was observed for the
Kellgren Lawrence Criteria for diagnosis, with 79% Grade
2 and 21% Grade 3 indicating that the majority of subjects
had mild osteoarthritis of the knee. When the four treat-
ment groups were compared there was no statistical differ-
ence in disease activity on entry – for ARAF-Class, Chi
square = 0.586, p = 0.900; Kellgren Lawrence Criteria, Chi
square = 0.690, p = 0.876.
Primary Efficacy Variable – WOMAC
Baseline disease activity was comparable in all 4 treatment
groups (Table 3). While all four groups displayed an
improvement from baseline for WOMAC values (subsets
and total) over the course of 8 weeks of treatment (p <
0.001), including placebo, the magnitude of these bene-
fits were greater in all 3 sierrasil groups (A, B and C). It is
of note that after 4 weeks of treatment the placebo treated
group (D) was not significantly different from baseline for
Table 7: Sequential WOMAC Total – Summary
Group Baseline Week 1 Week 2 Week 4 Week 6 Week 8
Placebo 48.6 ± 5.2 49.0 ± 5.8 46.6 ± 5.9 43.5 ± 5.8 38.8 ± 5.9 * 35.3 ± 6.3 **
A 51.5 ± 6.4 43.5 ± 6.9 41.4 ± 6.7 ** 35.0 ± 6.2 *** 36.2 ± 6.2 *** 31.8 ± 6.1 ***
B 46.4 ± 5.6 42.0 ± 5.9 * 38.6 ± 6.0 *** 32.6 ± 5.2 *** 31.5 ± 5.3 *** 28.5 ± 3.9 ***
C 44.8 ± 5.5 42.3 ± 5.2 39.0 ± 5.1 ** 32.0 ± 4.4 *** 28.7 ± 4.5 *** 25.6 ± 4.4 ***
Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + 
cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the 
Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, ** p < 0.001. 
Note the p values for groups A and C approached significance at week one (p = 0.051 and 0.053).
Sequential changes in WOMAC A (pain) scores expressed as  a percentage of baseline values Figure 1
Sequential changes in WOMAC A (pain) scores expressed as 
a percentage of baseline values. Placebo (blue, n = 22), high 
dose sierrasil (green, n = 20), low dose sierrasil (red, n = 21) 
and low dose sierrasil + cat's claw extract (orange, n = 25) all 
demonstrated a time dependent improvement in the pain 
indices of WOMAC A. However, in the placebo group this 
was delayed until the last month of the study. All sierrasil 
treated groups displayed a faster onset of action.
Sequential changes in WOMAC B (stiffness) scores  expressed as a percentage of baseline values Figure 2
Sequential changes in WOMAC B (stiffness) scores 
expressed as a percentage of baseline values. Placebo (blue, n 
= 22), high dose sierrasil (green, n = 20), low dose sierrasil 
(red, n = 21) and low dose sierrasil + cat's claw extract 
(orange, n = 25) displayed a time dependent improvement in 
WOMAC B scores, measuring stiffness, over the course of 
the study. A trend for a faster onset of improvement was evi-
dent in all sierrasil treated groups when compared to pla-
cebo controls.Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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any of the WOMAC scores, yet for groups A, B and C there
was a marked improvement over baseline (p < 0.001).
Indeed, statistically significant benefits were evident with
one week of treatment for many of the tests in sierrasil
treated subjects (Tables 4, 5, 6, 7).
Specifically, for group A (high dose) WSA, WSB and WST
were significantly improved at week 1 (p < 0.05). At week
2 for group A, all WOMAC scores were significantly
improved (p < 0.05). For group B (low dose), WSB, WSC,
and WST were significantly improved at week 1 (p < 0.05).
After 2 weeks of therapy in group B, all WOMAC scores
were significantly improved (p < 0.01). For group C (low
dose sierrasil + cat's claw extract) WSA was significantly
improved from baseline (p < 0.01) and by week 2 all
WOMAC scores except WSB were improved (p < 0.05).
These early benefits are readily apparent in Table 4, 5, 6,
and Figures 1, 2, 3, 4 which displays the percentage
changes from baseline for WOMAC A, WOMAC B,
WOMAC C, and WOMAC total respectively. However,
when the test groups were compared to placebo, the
magnitude of these differences were not significant for the
majority of time points (Friedman test).
Secondary Efficacy Variables – VAS
The VAS, a pain assessment, was significantly improved in
all 4 treatment groups at the conclusion of the study
(week 8, p < 0.001), Table 8. The placebo group (D) also
displayed a significant improvement in VAS at 4 weeks as
did groups A-C (P < 0.01) although, the magnitude of VAS
reductions in these sierrasil groups (A-C) at week 4 were
significantly greater than placebo (p < 0.05). However, the
greater response in groups A-C vs. placebo, was not statis-
tically significant at week 8 or other time points. Changes
in VAS expressed as a percentage of change from baseline
are shown in Figure 5.
Secondary Efficacy Variable – Rescue Medication
Paracetamol was used as a rescue medication with dosing
limited to 4 × 500 mg per day. There were no significant
differences in the use of paracetamol in the 4 treatment
groups (Figure 6), although some trends are clear. In
group A, there was a 23% lower use of paracetamol (p =
0.193 v placebo). For group C there was a 28% reduction
in paracetamol use, which approached significance when
compared to placebo (p = 0.101) or low dose sierrasil
alone (p < 0.055). The consumption of rescue medication
was not assessed at sequential timepoints. Furthermore,
the trend for greater consumption of rescue medication in
the placebo and low dose sierrasil groups may have
Sequential changes in WOMAC C (physical activity) scores  expressed as a percentage of baseline values Figure 3
Sequential changes in WOMAC C (physical activity) scores 
expressed as a percentage of baseline values. Placebo (blue, n 
= 22), high dose sierrasil (green, n = 20), low dose sierrasil 
(red, n = 21) and low dose sierrasil + cat's claw extract 
(orange, n = 25) displayed a time dependent improvement in 
physical activity and function scores (WOMAC C). A trend 
for a faster onset of benefits was evident in all sierrasil 
treated groups versus placebo.
Sequential changes in WOMAC total scores expressed as a  percentage of baseline values Figure 4
Sequential changes in WOMAC total scores expressed as a 
percentage of baseline values. Placebo (blue, n = 22), high 
dose sierrasil (green, n = 20), low dose sierrasil (red, n = 21) 
and low dose sierrasil + cat's claw extract (orange, n = 25) 
displayed a time dependent improvement in total WOMAC 
Scores. There was a trend for a faster onset of action in all 
sierrasil treated groups when compared to placebo 
responses.Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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masked the ability to determine significant differences
between groups in terms of the magnitude of pain and
discomfort relief.
Secondary Efficacy Variables – Global Assessments and 
Tolerance
Two global assessments to treatment were determined –
patient self assessment and the investigator's assessment.
For both perspectives 49% responded that the response
was good to excellent, however there was no statistical dif-
ference between treatment groups Patient's response: Chi
square = 8.118, p = 0.776.
Investigator's response: Chi square = 4.336, p = 0.888
Tolerance was reported as "good" by 94/95 subjects. The
one subject that reported a poor tolerance received high
dose sierrasil (group A).
Safety Variables – Laboratory
All laboratory tests were unchanged from baseline to week
8 for all groups with the following exceptions.
Table 8: Sequential VAS – Pain Index
Group Baseline Week 1 Week 2 Week 4 Week 6 Week 8
Placebo 72.9 ± 2.1 71.4 ± 2.7 68.4 ± 3.2 63.9 ± 3.3 ** 58.6 ± 3.9 ** 52.0 ± 4.7 ***
A 72.9 ± 3.0 66.8 ± 3.3 62.5 ± 4.7 ** 51.2 ± 5.0 *** 49.7 ± 5.1 *** 42.7 ± 5.2 ***
B 70.1 ± 2.5 65.8 ± 3.2 58.9 ± 3.8 ** 52.0 ± 4.7*** 51.9 ± 5.0 *** 44.6 ± 4.9 ***
C 70.7 ± 2.4 65.0 ± 2.6 60.7 ± 2.9 ** 52.7 ± 2.5 *** 47.2 ± 3.4 *** 43.4 ± 3.8 ***
Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + 
cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using a 
Wilcoxan matched pairs Signed-Rank test from baseline; * p < 0.05, ** p < 0.01, *** p < 0.001.
Sequential changes in VAS (pain) expressed as a percentage  of baseline values Figure 5
Sequential changes in VAS (pain) expressed as a percentage 
of baseline values. Placebo (blue, n = 22), high dose sierrasil 
(green, n = 20), low dose sierrasil (red, n = 21) and low dose 
sierrasil + cat's claw extract (orange, n = 25) displayed a time 
dependent improvement in VAS scores for pain. However, 
there was a trend for a faster onset of benefits in the sierrasil 
treated groups compared to placebo.
Consumption of rescue medication (paracetamol) for the  study duration Figure 6
Consumption of rescue medication (paracetamol) for the 
study duration. Results for placebo (blue column, n = 19), 
high dose sierrasil (green column, n = 19), low dose sierrasil 
(red column, n = 20) and low dose sierrasil + cat's claw 
extract (orange column, n = 23) groups are expressed as 
mean ± sem. There was no significant difference in rescue 
medication use between the various groups, although a trend 
for less paracetamol consumption was evident in both the 
high dose sierrasil and low dose + cat's claw groups which 
approached significance (p = 0.119 and p = 0.101 vs placebo 
respectively).Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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(1) Group A hemoglobin was increased from 12.0 ± 0.2 to
12.5 ± 0.3, p < 0.05
(2) Group B lymphocyte levels increased from 30.3 ± 1.8
to 34.3 ± 1.8, p < 0.05
These changes, while statistically significant, were not
considered as indicative of an adverse response based on
values observed in the other groups. A summary of these
safety variables is depicted in Table 9.
Safety Variables – Vital Signs
Blood pressure (systolic and diastolic), respiration rate
and pulse rate were vital signs that were monitored. Using
ANOVA there was no change in these variables from
screening for the study, at the 5 intermediate evaluation
points and the study's conclusion at 8 weeks, with the fol-
lowing exceptions.
(1) Pulse rate declined in Group B (p < 0.05) from a
screening value of 81.4 ± 1.5 to 76.2 ± 1.2 beats per
minute at week 8.
(2) Respiration rate declined in Group C (p < 0.05) from
a screening value of 19.3 ± 0.6 to 18.9 ± 0.4 breaths per
minute
Data for baseline vital sign values and again at week 8 are
depicted in Table 10. Data for screening and the interven-
ing assessments at weeks 1, 2, 4 and 6 are not included for
simplicity.
Discussion
The purpose of this study was to determine if the natural
mineral supplement, sierrasil, would relieve the symp-
toms of mild to moderate osteoarthritis of the knee in a
safe manner. The approach included two doses of the
mineral supplement to encompass the anecdotal clinical
experience, and to evaluate the inclusion of a botanical
extract, cat's claw (vincaria), which had previously been
shown to be effective in treating osteoarthritis [10]. Using
a randomized, double-blind placebo-controlled multi-
center design, it is clear that this mineral supplement is
indeed safe. Treatments were efficacious, particularly
compared to baseline conditions, but there were clear
difficulties in determining a sustained disassociation from
placebo. In all sierrasil treated groups there was a
significantly faster onset of benefits from initial values
(evident from week 1 to 2) compared to placebo (first evi-
dent at week 6) but at the conclusion of the study differ-
ences between groups was not significant.
While it is of interest that the sierrasil that provided early
relief of symptoms the inability to establish sustained
significant differences from placebo poses limitations on
interpretation. In part this dilemma is the result of the
small study group size in this preliminary clinical evalua-
tion. Additionally, an unexpected sharp improvement in
primary and secondary assessments in the placebo group
at weeks 6 & 8 contributed to the study's limitations.
While clearly not in the instructions, subjects may have
had expectations that all potential treatments in the rand-
omized protocol would provide benefits and this may
account for the placebo response. However, if this were
Table 9: Laboratory-based evaluations of safety
Test Placebo Wk. 
0
Placebo Wk. 
8
A Wk. 0 A Wk. 8 B Wk. 0 B Wk. 8 C Wk. 0 C Wk. 8
Neu 62.0 ± 1.7 64.2 ± 2.1 59.3 ± 2.4 58.6 ± 2.3 64.7 ± 1.6 61.5 ± 1.6 61.6 ± 1.5 63.0 ± 1.7
Bas 0000000 0 . 3  ±  0 . 3
Eos 3.6 ± 0.8 3.6 ± 0.6 4.2 ± 0.5 3.7 ± 0.9 4.0 ± 0.6 4.8 ± 1.5 3.9 ± 0.5 4.4 ± 0.5
Lym 34.0 ± 2.0 31.7 ± 2.5 35.7 ± 2.5 35.2 ± 1.8 30.3 ± 1.8 34.3 ± 1.8* 33.4 ± 1.7 31.8 ± 1.8
Mon 0.8 ± 0.3 0.6 ± 0.2 1.0 ± 0.2 0.8 ± 0.3 0.9 ± 0.2 0.7 ± 0.2 1.1 ± 0.2 0.7 ± 0.2
WBC 8052 ± 417 8260 ± 499 7994 ± 514 8037 ± 655 8750 ± 476 7857 ± 478 8160 ± 308 7815 ± 459
RBC 3.98 ± 0.09 4.11 ± 0.11 4.26 ± 0.09 4.41 ± 0.12 4.33 ± 0.11 4.31 ± 0.10 4.39 ± 0.12 4.30 ± 0.10
HB 12.0 ± 0.2 12.4 ± 0.4 12.0 ± 0.2 12.5 ± 0.3* 12.2 ± 0.3 12.1 ± 0.3 12.3 ± .2 12.2 ± 0.3
ESR 29.0 ± 3.6 32.4 ± 6.0 35.0 ± 3.5 30.5 ± 4.8 31.7 ± 4.2 40.7 ± 6.2 26.5 ± 3.6 22.2 ± 3.2
SGPT 28.8 ± 1.9 27.7 ± 2.4 23.6 ± 1.9 29.3 ± 4.5 24.5 ± 1.6 25.6 ± 1.7 24.9 ± 1.1 26.4 ± 3.3
CRE 0.98 ± 0.04 0.97 ± 0.05 1.4 ± 0.4 0.9 ± 0.04 1.7 ± 0.7 1.0 ± 0.03 1.67 ± 0.69 1.01 ± 0.05
Data expressed as a mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + 
cat's claw extract (n = 25), placebo n = 22.
Neu = neutrophils %, Bas = basophils %, Eos = eosinophils %, Lym = lymphocytes %, Mon = monocytes %, WBC = white blood cells per mm3, RBC 
= red blood cells 106 × mm3, HB = hemoglobin gm/dl, ESR = erythrocyte sedimentation rate mm, SGPT = IU/L, CRE = creatinine mg/dl. Using 
unpaired t test, the following descriptors describe a significant difference from baseline, * p < 0.05.Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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the case one may expect that this placebo effect would be
continuous as opposed to an exaggerated response that
was observed in the last month of a two month study.
Another important consideration is a potential masking
effect of rescue medication use. Rescue medication use
was greater in placebo and low dose sierrasil groups, and
this may have masked differences between the positive
benefits related to treatment and placebo. Total consump-
tion of rescue medication was determined and so it is not
possible to link changes in rescue medication to perceived
changes in disease activity on a weekly or monthly basis.
With the sierrasil test groups significant reductions in the
baseline values of the primary efficacy variable, WOMAC,
were evident as early as week 1 with steady improvements
with continued administration (Figs. 1, 2, 3, 4). In
contrast, placebo treated subjects did not report signifi-
cant benefits from baseline until week 6. This early onset
of benefits is not inconsistent with the in vitro studies
demonstrating the protection of human cartilage
degradation induced by IL-1β, which was prevented by
acute exposure to sierrasil [25]. These human cartilage
explant studies also demonstrated that the activation of
nitric oxide production, a catabolic pathway [30-32], was
attenuated by sierrasil. However, the present study does
not directly assess whether protection of against cartilage
degradation was associated with the therapies, nor is it
likely that a substantial change in joint architecture would
occur in this timeframe.
Of note, co-administration of the Uncaria guianensis
extract, vincaria, was also chondroprotective in vitro [29]
and associated with a rapid onset of benefits in
osteoarthritis as noted in a separate double blind placebo
controlled study [10]. Cat's claw has considerable data
demonstrating that it is an effective inhibitor of transcrip-
tion via NF-κB [36] and this formulation is a quite potent
inhibitor of tumor necrosis factor [37,38]. Thus, both sier-
rasil and vincaria have the potential to act as disease mod-
ifying agents in osteoarthritis although only safety and
symptomatic relief were the focal issues of this prelimi-
nary clinical study.
As this mineral supplement is relatively unknown it was
important to evaluate safety as well as efficacy. In this 2
month study there were no changes in various clinical and
laboratory measures of safety. The study design included
an evaluation of mineral supplement dose (2 vs. 3 g/day)
and the herbomineral combination. The reason for evalu-
ating these somewhat similar doses reflects the anecdotal
clinical experience with these doses, which brought sug-
gestions that the higher dose necessitated a more rigorous
assessment. There was little difference between these
groups although a better defined week 1 and 2 responses
with the high dose were evident. The herbomineral com-
bination produced a greater percentage reduction in
WOMAC scores and both groups were associated with
reduced consumption of rescue medications. This sug-
gests that these approaches provided additional value but
a definitive statistical difference to advocate a higher dose
or the herbomineral combination was not achieved. How-
ever, with a greater subject enrolment these trends would
likely have reached significance.
VAS, as an index of pain, was responsive to both treatment
as well as placebo. While there were significant differences
at 1 month between mineral supplement treatments and
placebo this was not statistically evident at 2 months.
Indeed there was a trend for an exaggerated placebo effect
for many efficacy variables from week 4 to week 8.
VAS is regarded as being a less sensitive index of disease
activity than the WOMAC scores, which assess pain as well
as stiffness and physical activity/function. The similar
trends for earlier symptomatic relief in sierrasil treated
subjects in the all three WOMAC subsets, as well as VAS
pain, within the first month was noticeable and readily
Table 10: Vital Signs
Vital Sign Placebo Wk 
0
Placebo Wk 
8
A Wk. 0 A Wk. 8 B Wk. 0 B Wk. 8 C Wk. 0 C Wk. 8
Pulse Rate 80.3 ± 1.3 76.9 ± 1.1 79.1 ± 1.3 74.7 ± 0.9 80.7 ± 1.3 76.1 ± 1.2 78.6 ± 0.9 76.6 ± 0.9
Systolic BP 128 ± 1 130 ± 2 129 ± 2 130 ± 3 132 ± 2 129 ± 3 * 129 ± 1 128 ± 2
Diastolic BP 8 3  ±  18 6  ±  18 2  ±  18 2  ±  18 3  ±  18 2  ±  18 0  ±  18 0  ±  2
Respiration 
Rate
19.5 ± 0.7 19.9 ± 0.7 19.2 ± 0.6 18.9 ± 0.4 19.7 ± 0.7 19.4 ± 0.8 20.2 ± 0.5 18.5 ± 0.5 *
Data expressed as a mean ± sem. Units of measure were: Pulse rate (beats per min), systolic and diastolic blood pressure (mm Hg), respiration rate 
(breaths per minute). Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw 
extract (n = 25), placebo n = 22. Pulse rate and respiration rate are given as the rate per minute and blood pressure is expressed in mm Hg. Using 
unpaired t test, the following descriptors describe a significant difference from baseline, *p < 0.05.Journal of Inflammation 2005, 2:11 http://www.journal-inflammation.com/content/2/1/11
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distinguishable from placebo treated individuals (Figs 1,
2, 3, 4, 5). Indeed, the similar trends in these three
treatment groups when taken together suggest that this
therapeutic approach has a clear early onset of benefits.
The mechanisms by which this natural mineral supple-
ment achieves these actions and benefits is unclear. The
study in human explants indicates that it may affect
transcriptional events, as indicated by the reduced
production of nitric oxide in response to IL-1β. Increased
production of nitric oxide under these circumstances is
attributed to the expression of inducible nitric oxide syn-
thase [31,35]. A decade ago we defined that this nitric
oxide isoform promoted chronic inflammation [34,35]
and inhibitors alleviate numerous inflammatory condi-
tions including arthritis [30].
The protection of matrix degradation in response to IL-1
by sierrasil may reflect a reduction in matrix metallopro-
tease (MMP) production (also transcriptionally regulated
in response to IL-1β) or perhaps a direct interference in
the activity of MMPs. There is no evidence for the later but
is speculated based on the mineral/metal content of sier-
rasil and the requirement of metals as catalysts in MMPs.
Studies by the manufacturer on the acid liberalization of
minerals from sierrasil suggest that the majority of the
minerals within sierrasil are tightly bound and are not
freely bioavailable (data not shown). Additionally, while
the ingestion of supplemental minerals may alter the
basal nutritional status of the subjects the literature does
not provide a clear link between a nutrition-based action
of minerals and an effective anti-arthritic therapy [43]. It
is speculated that a micromineral action on gene
expression or direct interaction with MMPs may be an
alternative action to consider.
A critical issue is how to place these findings in a therapeu-
tic perspective. Osteoarthritic patients, and their health-
care providers, are deeply concerned with the recent
documentation of an increased risk for cardiovascular dis-
ease and stroke with COX-2 inhibitors [4,5], as well as the
significant gastro-intestinal, renal complications and pre-
mature deaths associated with non-selective COX inhibi-
tors [3]. With the appreciation that the NSAID class
provides symptomatic relief rather that abrogating the dis-
ease process [2], there is a great need for alternatives.
Despite the potential of redox-based botanicals as anti-
inflammatory agents [11], the most commonly used nat-
ural product approach to the management of osteoarthri-
tis is glucosamine and chondroitin [43]. While early
studies suggested excellent albeit slow-onset responsive-
ness [15-17], more recent studies have suggested that the
benefits offered by glucosamine and chondroitin may
have limitations or be variable in nature [13,18-21]. One
recent study suggested that continued use of glucosamine
may be unwarranted, even if there were initial benefits
[44]. Clarification as to therapeutic potential of this
approach is likely to occur when the results of the
Glucosamine Arthritis Intervention Trial, with 1588 sub-
jects from 13 centers randomized to 5 treatment groups.
While sierrasil was noted to produce early benefits but it
was not clearly established that sustained actions were
indistinguishable from placebo. Similar issues have been
raised with glucosamine and chondroitin, as well as
cetylated fatty acids, where there is some evidence that
after 2 months of therapy there are reductions in pain and
flexibility but no benefits related to physical function/
activity [9].
Conclusion
In summary, the natural mineral supplement sierrasil,
alone and in combination with an extract of the Amazo-
nian medicinal plant, cat's claw (Uncaria guianensis),
provide a rapid relief of osteoarthritis symptoms. The ben-
efits were evident within a week, and associated with an
excellent safety profile. However, a lack of discrimination
between treatment and placebo, especially with sustained
administration, limits the assessment sierrasil's role in the
treatment of osteoarthritis. Nevertheless, as alternative
approaches to the management of osteoarthritis are desir-
able, sierrasil may offer a valuable option for some
subjects.
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